Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Hemorheol Microcirc ; 82(4): 335-340, 2022.
Article in English | MEDLINE | ID: mdl-35938241

ABSTRACT

BACKGROUND: Although inflammation and thrombosis are tightly connected, only 45% of patients with lower leg cellulitis receive anticoagulant therapy. Available data about the prevalence of concomitant deep venous thrombosis (DVT) in patients with cellulitis of the lower extremity is scarce and general guidelines regarding diagnosis and prevention of venous thromboembolism are missing. OBJECTIVE: We sought to determine how frequently DVT occurs as an incidental finding in patients with cellulitis and to provide recommendations for diagnostics and anticoagulant therapy. METHODS: Patients' records were analysed and 192 consecutive patients with cellulitis were included in this study. The prevalence of concomitant DVT was examined by duplex ultrasound, as well as comorbidities and risk factors. RESULTS: We detected thrombosis in 12.0% of the patients with lower leg cellulitis, of which 43.5% were located in a proximal vein and 52.2% in the veins of the calf. CONCLUSIONS: Our results clearly indicate that cellulitis is not only a differential diagnosis, but should be considered a risk factor for venous thrombosis. Therefore, prophylactic anticoagulation should be considered in patients suffering from cellulitis and a systematic screening for venous thrombosis in patients with cellulitis should be performed.


Subject(s)
Cellulitis , Venous Thrombosis , Humans , Cellulitis/complications , Cellulitis/diagnosis , Cellulitis/epidemiology , Incidental Findings , Lower Extremity/blood supply , Venous Thrombosis/complications , Venous Thrombosis/diagnosis , Venous Thrombosis/drug therapy , Risk Factors , Anticoagulants/therapeutic use
2.
Drugs R D ; 16(3): 279-283, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27623792

ABSTRACT

Rosacea is a chronic inflammatory disease that can manifest as a spectrum of symptoms including erythema, inflammatory lesions, edema, and telangiectasia. Treatment decisions need to be adapted to reflect the nature and severity of the different symptoms present. In this report, we discuss the case of a female patient diagnosed with severe, inflamed papulopustular rosacea (PPR) presenting with a large number of inflammatory lesions and severe background erythema. This patient responded well to a treatment regimen consisting of a short course of antibiotics in combination with a corticosteroid, followed by monotherapy with isotretinoin to reduce the inflammation. Brimonidine gel, used as needed, was then added to isotretinoin to target the remaining background erythema. This case of severe PPR required a combinatorial treatment regimen to effectively target all symptoms present. The patient continued to apply topical metronidazole throughout the different treatment regimens prescribed over the course of almost 1 year. Use of topical metronidazole helped to repair and protect the skin barrier, which minimized the occurrence of dermatological adverse events when topical treatments were used. We conclude that in patients with severe disease and an important inflammatory component, a rapid response can be obtained with a multimodal, tailored approach that also includes treatment to repair and protect the skin barrier.


Subject(s)
Administration, Topical , Anti-Bacterial Agents/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Dermatologic Agents/therapeutic use , Isotretinoin/therapeutic use , Rosacea/drug therapy , Adult , Anti-Bacterial Agents/administration & dosage , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/metabolism , Brimonidine Tartrate , Dermatologic Agents/administration & dosage , Drug Therapy, Combination , Female , Humans , Isotretinoin/administration & dosage , Metronidazole/therapeutic use , Prednisolone
3.
J Invest Dermatol ; 135(3): 759-767, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25347115

ABSTRACT

In healthy human skin host defense molecules such as antimicrobial peptides (AMPs) contribute to skin immune homeostasis. In patients with the congenital disease ectodermal dysplasia (ED) skin integrity is disturbed and as a result patients have recurrent skin infections. The disease is characterized by developmental abnormalities of ectodermal derivatives and absent or reduced sweating. We hypothesized that ED patients have a reduced skin immune defense because of the reduced ability to sweat. Therefore, we performed a label-free quantitative proteome analysis of wash solution of human skin from ED patients or healthy individuals. A clear-cut difference between both cohorts could be observed in cellular processes related to immunity and host defense. In line with the extensive underrepresentation of proteins of the immune system, dermcidin, a sweat-derived AMP, was reduced in its abundance in the skin secretome of ED patients. In contrast, proteins involved in metabolic/catabolic and biosynthetic processes were enriched in the skin secretome of ED patients. In summary, our proteome profiling provides insights into the actual situation of healthy versus diseased skin. The systematic reduction in immune system and defense-related proteins may contribute to the high susceptibility of ED patients to skin infections and altered skin colonization.


Subject(s)
Ectodermal Dysplasia/immunology , Ectodermal Dysplasia/metabolism , Peptides/metabolism , Proteomics , Skin/metabolism , Adult , Animals , Case-Control Studies , Disease Models, Animal , Female , Gene Expression Profiling , Humans , Male , Mice , Mice, Inbred C57BL , Ointments , Peptides/administration & dosage , Peptides/therapeutic use , Staphylococcal Skin Infections/drug therapy , Staphylococcal Skin Infections/microbiology , Staphylococcus aureus , Sweat Glands/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...